The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment

Frleta, M., Siebert, S. and McInnes, I. B. (2014) The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment. Current Rheumatology Reports, 16(414), (doi:10.1007/s11926-014-0414-y) (PMID:24570394)

Full text not currently available from Enlighten.

Abstract

Psoriasis and psoriatic arthritis (PsA) are pathophysiological enigmas among rheumatic diseases. Substantial clinical advances have been made with new therapy targeting different components of the IL-17 and IL-23 pathways. At the same time, an increase in research on the topic has provided new insights into the potential functional effects of treatments on cell types, pathways, and tissues of interest. Here we review our knowledge of all IL-17 family members, their relationships with the IL-23 pathway, and the outcomes of relevant clinical trials in which different strategies for targeting these molecules have been tested in the treatment of moderate to severe psoriasis and PsA.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McInnes, Professor Iain and Frleta, Dr Marina and Siebert, Dr Stefan
Authors: Frleta, M., Siebert, S., and McInnes, I. B.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Current Rheumatology Reports
Publisher:Springer US
ISSN:1523-3774
ISSN (Online):1534-6307

University Staff: Request a correction | Enlighten Editors: Update this record